SM
SBFM

Sabby Management’s Sunshine Biopharma SBFM Stock Holding History

Sabby Management’s Portfolio SBFM Stock Details SBFM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-156
Closed -$2.24K – 58
2025
Q2 		$2.24K Buy
+156
New +$2.28K ﹤0.01% 43
2024
Q3 		– Sell
-100
Closed -$8.35K – 58
2024
Q2 		$8.35K Buy
+100
New +$47.7K 0.01% 38

Other funds holding SBFM

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return

Sabby Management's SBFM Position: Q3 2025 in Review

Sabby Management sold out of Sunshine Biopharma (SBFM) in Q3 2025, closing a stake of 156 shares — an estimated $2.24K sold.

Sabby Management first reported a position in SBFM in Q2 2024 and held it in 2 quarters. The position peaked at $8.35K in Q2 2024. 11 funds tracked by Wall St. Rank hold SBFM as of Q3 2025.

  • Sabby Management reported no remaining Sunshine Biopharma position as of Q3 2025 after selling out during the quarter.
  • Sabby Management sold 156 Sunshine Biopharma shares in Q3 2025, an estimated $2.24K.
  • Sabby Management first reported a position in Sunshine Biopharma in Q2 2024 and held it in 2 quarters.
  • Sabby Management's Sunshine Biopharma position peaked at $8.35K in Q2 2024.
  • 11 funds tracked by Wall St. Rank held Sunshine Biopharma as of Q3 2025.

Based on Sabby Management's 13F filing for Q3 2025, filed 14 Nov 2025.